Vaccines PRODUCT TYPE COUNTRY/REGION aTIV (unbranded) Trivalent Influenza Vaccine, Adjuvanted (surface antigen, inactivated, egg-based) NR United Kingdom aTIV (unbranded) Trivalent Influenza Vaccine, Adjuvanted (surface antigen, inactivated, egg-based) NI United Kingdom (for the prevention of influenza in persons aged 50 yrs+) aQIV (unbranded) Quadrivalent Influenza Vaccine, Adjuvanted (surface antigen, inactivated, egg-based) NI United Kingdom (for the prevention of influenza in persons aged 50 yrs+) ALFUNOV® Influenza Vaccine Zoonotic Monovalent, Adjuvanted (inactivated, egg-based) NI European Union (for the prevention of influenza in persons aged 6 m+) CELLDEMIC® Influenza (H5N1) Vaccine Zoonotic Monovalent, Adjuvanted (inactivated, cell-based) NR United Kingdom, Australia FLUAD® Trivalent Influenza Vaccine, Adjuvanted (surface antigen, inactivated, egg-based) NR European Union, Taiwan FLUAD® Trivalent Influenza Vaccine, Adjuvanted (surface antigen, inactivated, egg-based) NI Argentina (for the prevention of influenza in persons aged 50 yrs+) FLUCELVAX® Trivalent Influenza Vaccine (surface antigen, inactivated, cell-based) NR European Union, Canada, Korea, Argentina, Taiwan * First-time registrations or indications for CSL products in the listed countries/ regions over the reporting period. 1. FILSPARI® licensed from Travere Therapeutics. 2. FILSPARI® conditionally approved in Switzerland under Article 9b TPA, subject to post-approval obligations. 3. TAVNEOS® is a registered trademark of ChemoCentryx Inc. 4. In the United states, VELPHORO® NDA is owned by Vifor Fresenius Medical Care Renal Pharma France (VFMCRPF) and distributed by Fresenius Medical Care North America. 5. In some markets, INCELLIPAN® is marketed as AUDENZ®. PRODUCT TYPE COUNTRY/REGION FLUCELVAX® Trivalent Influenza Vaccine (surface antigen, inactivated, cell-based) NI European Union (for the prevention of influenza in persons aged 6 m+) TIVc (unbranded) Trivalent Influenza Vaccine (surface antigen, inactivated, cell-based) NR United Kingdom FLUCELVAX® TETRA Quadrivalent Influenza Vaccine (surface antigen, inactivated, cell-based) NI European Union (for the prevention of influenza in persons aged 6 m+), Switzerland (for the prevention of influenza in persons aged 2 yrs+) AUDENZ®/ INCELLIPAN® Influenza Pandemic Vaccine Monovalent, Adjuvanted (inactivated, cell-based)5 NR United Kingdom, Australia KOSTAIVE® sa-mRNA COVID-19 Vaccine NR European Union PANVAX® Influenza (H5N8) Pre-pandemic Vaccine Zoonotic Monovalent, Adjuvanted (egg-based) NR New Zealand ZOONOTIC INFLUENZA VACCINE (unbranded) Influenza Vaccine Zoonotic Monovalent, Adjuvanted (inactivated, egg-based) NI European Union, United Kingdom (for the prevention of influenza in persons aged 6 m+) Develop products for the prevention of infectious diseases Cardiovascular & Renal Improving and extending the lives of patients with cardiovascular and renal diseases PRODUCT TYPE COUNTRY/REGION FILSPARI® Dual ETA & AT1 antagonist (IgAN)1 NR United Kingdom, Switzerland2 TAVNEOS® Oral C5a Receptor Inhibitor (AAV)3 NR China, Brazil, Russia VELPHORO® Sucroferric oxyhydroxide (Serum P control in CKD)4 NI United States (for patients 9 yrs+ with CKD on dialysis) VELTASSA® Oral Potassium Binder (HK) NR Japan 23 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3